A digital pathology company has raised $23 million in Series B funding as it seeks to push its cancer-detecting software into new markets.
Proscia’s software – called Concentriq – is essentially an operating system for digital scanners used in the analysis of tissue biopsies. It allows users to view, store and analyze digital images and to launch companion apps developed by Proscia and by third parties. Proscia’s DermAI app, for example, can triage skin-tissue biopsies so that high-risk cases get attention.
Contentriq’s customers include the Joint Pathology Center, a U.S. government reference center that is using the Proscia platform to digitize its archive of roughly 55 million glass slides. Proscia also is partnering with University Medical Center Utrecht in The Netherlands to drive the use of computational pathology in clinical practice.
